Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
about
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicineNext-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?Teaching residents genomic pathology: a novel approach for new technologyNavigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnosticsGenome sequencing and cancerAnnotating individual human genomesGenetic and epigenetic traits as biomarkers in colorectal cancerClinical tumor sequencing: opportunities and challenges for precision cancer medicineCIViC databaseProspective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trialsOrganizing knowledge to enable personalization of medicine in cancer'Omic approaches to preventing or managing metastatic breast cancerPathway-driven discovery of rare mutational impact on cancerPersonalized identification of altered pathways in cancer using accumulated normal tissue data.Using large-scale molecular data sets to improve breast cancer treatment.Comprehensive whole genome sequence analyses yields novel genetic and structural insights for Intellectual Disability.Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancerConsistency-based detection of potential tumor-specific deletions in matched normal/tumor genomesProgress and potential: training in genomic pathologyJointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data.What are we learning from the cancer genome?Applying next-generation sequencing to pancreatic cancer treatment.Can we deconstruct cancer, one patient at a time?In depth comparison of an individual's DNA and its lymphoblastoid cell line using whole genome sequencing.Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trialThe business of genomic testing: a survey of early adopters.Pharmacogenomics: will the promise be fulfilled?Insight into the heterogeneity of breast cancer through next-generation sequencing.BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceTranslating cancer 'omics' to improved outcomes.Getting a head start: the importance of personal genetics education in high schools.Whole-genome sequencing for optimized patient managementC3 Vertebral Metastases From Tongue Adenoid Cystic Carcinoma: A Rare Case Report.A cancer cell-line titration series for evaluating somatic classification.Can intensive longitudinal monitoring of individuals advance cancer research?A somatic reference standard for cancer genome sequencing.The future of genomics in pathology.Clonal competition with alternating dominance in multiple myeloma.Sequencing Strategies to Guide Decision Making in Cancer Treatment.Drug repositioning for personalized medicine.
P2860
Q26748603-D49BC33A-DFE7-4C8B-9C13-98EBE9FA7B7AQ26781271-922CD1F9-819F-4091-9A7E-6470920095B8Q26859129-7D664CF4-F033-4EDC-8794-6DD873F0990DQ26864332-E51FADF3-4C32-42A2-AFE9-D45E480F6BB9Q26998499-2F6538B9-E38D-44F4-BAF1-BAEB59FF470EQ26999723-FB8195A9-0127-42B7-9E1E-8D3CAC778317Q27016019-4085CEE1-4CA6-4796-A46A-05F025F382E5Q27027942-D1E98D09-28B7-441E-A3C3-3289E3ACFADDQ27612411-F0747994-5836-4A0B-82DE-3F67D4108A13Q28540955-9695F7AE-5FB8-4965-987B-3F2810B9DAFCQ28652806-5A7E1071-5C74-4A30-90C9-A8507E605034Q28730572-D8A21A8D-1857-496A-9950-98A6FFD36165Q30363088-7BCE923B-9F6C-49EA-97F7-66634EBBC5E3Q30366103-53735BC9-07E4-492C-8134-1646CA4C1F3FQ30656126-4F1581CF-6D8E-4B4A-A687-0CF3FF59142DQ33721903-3F85BC9A-9E7E-44C6-BDEC-3D7B0EE05688Q33728359-31520648-09D4-418B-B342-49FF00BEA587Q34094829-A7916739-FF21-446B-8D92-63CEE4AA11AEQ34117277-A53731A0-3A70-46C5-B71C-242FAEE2E0BBQ34143680-0BB8A247-9FED-4CE6-9182-322F9CD226EEQ34213994-934520E3-B0B5-45ED-AE98-5FF551B6BB51Q34285351-08480035-4140-4CFB-9083-2CB5B9DB27A4Q34308476-87D4031E-20B3-4DFF-9E69-BC3CA86806E5Q34413907-D6CE1F5E-AEEC-42C8-B391-802BA337D8BFQ34544846-B0DF8817-7F4C-4ABC-BA14-08234E6F9024Q34675163-2F08EA1F-6F07-4984-A0DA-5784CA7FFF50Q34994860-7E40F0D4-02EA-4E24-B49E-42439FF9A719Q35370090-9765FDCF-3F21-442F-B5CD-A17E60EF0D02Q35607456-9B3CDDB0-FCB4-4B36-A3D7-A083D967B2F4Q35694365-74555B8B-3585-441C-8198-B89F5D5D0495Q35855495-FA416054-6E02-45EB-8DD8-B837BB7826D5Q35857612-EFD65193-D4B2-41A4-99D9-7F672AF71DD5Q35858085-74A1A1BA-8A26-4EE2-A131-34F23BDCBF50Q35879065-6B5AF0B5-133F-4018-8C5B-1FB047BEC762Q35989936-24ADFED3-BD2A-4F3D-BC94-1BE16BC97979Q35994200-0E4CE574-C3A6-4ADC-9ABF-9A8B3BF54D79Q36082163-C2653D23-05C6-4EF9-9C27-A3547EBC6DC8Q36141846-6AF08EAD-4E12-41AA-82FE-97A2FA0F6DDDQ36214189-0AAA08B0-F5D3-408A-A3E2-F603E678DF2FQ36245193-3E57E231-15B5-4D02-9833-A272E0F40945
P2860
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@ast
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@en
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@en-gb
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@nl
type
label
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@ast
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@en
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@en-gb
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@nl
prefLabel
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@ast
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@en
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@en-gb
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
@en
P2093
Angela Tam
Anthony P Fejes
David G Huntsman
Eric Chuah
Janessa Laskin
Jianghong An
Marco A Marra
Margaret Sutcliffe
Michael Mayo
P2860
P2888
P3181
P356
10.1186/GB-2010-11-8-R82
P407
P577
2010-01-01T00:00:00Z
P5875
P6179
1039133337